P53 fl 393 sc 6243

Manufactured by Santa Cruz Biotechnology

P53 (FL-393; sc-6243) is a full-length antibody that recognizes the p53 protein. p53 is a transcription factor that plays a crucial role in regulating cell cycle, apoptosis, and genomic stability. This antibody can be used for various applications, including Western blotting, immunoprecipitation, and immunofluorescence.

Automatically generated - may contain errors

Lab products found in correlation

Recombinant mouse m csf, by R&D Systems (1 mentions) Recombinant mouse rankl, by R&D Systems (1 mentions) Cd11b, by Thermo Fisher Scientific (1 mentions) Cisplatin, by Merck Group (1 mentions) Mhcii, by Thermo Fisher Scientific (1 mentions) Nutlin 3, by Selleck Chemicals (1 mentions) Recombinant opg, by Merck Group (1 mentions) Sca 1, by Thermo Fisher Scientific (1 mentions) Gapdh 14c10, by Cell Signaling Technology (1 mentions) Pe conjugated antimouse cd44, by BioLegend (1 mentions) Cd140a, by BioLegend (1 mentions) M csf, by R&D Systems (1 mentions) Rankl, by R&D Systems (1 mentions)

Close spelling variants of this product

FL-393 (46 citations) Sc-6243 (44 citations) P53 (FL-393, (13 citations) P53 (sc-6243, (12 citations)

2 protocols using p53 fl 393 sc 6243

Flow Cytometry and Western Blot Analysis of Cell Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used in flow cytometry: phycoerythrin (PE)-conjugated anti-mouse CD44 (Biolegend, 103007), Sca-I (eBioscience, 12-5981-83), CD140a (Biolegend, 135906), CD13 (BD Pharmingen, 558745), MHC II (eBioscience, 12-5320-80), CD11b (eBioscience,12-0112-83), CD11c (eBioscience, 12-0114-82), CD86 (eBioscience, 12-0862-82), and CD45 (eBioscience, 12-0451-82). Antibodies used for western blotting analysis were: anti-p53 (FL-393; sc-6243, Santa Cruz Biotechnology); GAPDH (14C10, 2118, Cell Signaling Technology). Antibody used for Chip was: p53 (FL-393; sc-6243, Santa Cruz Biotechnology), IgG (normal mouse IgG, sc2025, Santa Cruz Biotechnology). The reagents for cell treatment were: Nutlin-3 (Nutlin-3, Selleck Chemicals, Houston, TX, USA), Cisplatin (Sigma-Aldrich), RANKL (recombinant mouse RANKL, 50 ng/ml, R&D), M-CSF (recombinant mouse M-CSF, 25 ng/ml, R&D), and OPG (recombinant OPG, 50 ng/ml, Sigma-Aldrich). RANKL for mouse injection (recombinant mouse RANKL, 2 mg/kg/day) was from R&D Systems.

Velletri T., Huang Y., Wang Y., Li Q., Hu M., Xie N., Yang Q., Chen X., Chen Q., Shou P., Gan Y., Candi E., Annicchiarico-Petruzzelli M., Agostini M., Yang H., Melino G., Shi Y, & Wang Y. (2020). Loss of p53 in mesenchymal stem cells promotes alteration of bone remodeling through negative regulation of osteoprotegerin. Cell Death and Differentiation, 28(1), 156-169.

+ Open protocol

+ Expand

Chromatin Immunoprecipitation for p53 Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols

Chromatin immunoprecipitation was performed as previously described³⁰. Chromatin was immunoprecipitated with the p53 FL-393 (sc-6243, Santa Cruz Biotechnology) antibody. IgGs purified from rabbit serum were used as negative control. Co-immunoprecipitated DNA was analyzed by real-time PCR. Promoter occupancy was calculated as percent of input chromatin immunoprecipitated using the 2^−ΔCt method. Primers sequences are reported in the Supplemental Table 2.

Capaci V., Bascetta L., Fantuz M., Beznoussenko G.V., Sommaggio R., Cancila V., Bisso A., Campaner E., Mironov A.A., Wiśniewski J.R., Ulloa Severino L., Scaini D., Bossi F., Lees J., Alon N., Brunga L., Malkin D., Piazza S., Collavin L., Rosato A., Bicciato S., Tripodo C., Mantovani F, & Del Sal G. (2020). Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. Nature Communications, 11, 3945.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!